CN115768427B - 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 - Google Patents

癌症疗法中用于靶向降解不可靶向的kras的新型小分子 Download PDF

Info

Publication number
CN115768427B
CN115768427B CN202180049321.9A CN202180049321A CN115768427B CN 115768427 B CN115768427 B CN 115768427B CN 202180049321 A CN202180049321 A CN 202180049321A CN 115768427 B CN115768427 B CN 115768427B
Authority
CN
China
Prior art keywords
compound
kras
cancer
compounds
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180049321.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115768427A (zh
Inventor
B.皮莱
迪内什.M.G.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pillay Global LLC
Original Assignee
Pillay Global LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pillay Global LLC filed Critical Pillay Global LLC
Priority to CN202510275737.2A priority Critical patent/CN120208921A/zh
Publication of CN115768427A publication Critical patent/CN115768427A/zh
Application granted granted Critical
Publication of CN115768427B publication Critical patent/CN115768427B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202180049321.9A 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子 Active CN115768427B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510275737.2A CN120208921A (zh) 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041023434 2020-06-04
IN202041023434 2020-06-04
PCT/IB2021/054591 WO2021245499A1 (en) 2020-06-04 2021-05-26 Novel small molecules for targeted degradation of untargetable kras in cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510275737.2A Division CN120208921A (zh) 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子

Publications (2)

Publication Number Publication Date
CN115768427A CN115768427A (zh) 2023-03-07
CN115768427B true CN115768427B (zh) 2025-03-28

Family

ID=78830675

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180049321.9A Active CN115768427B (zh) 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子
CN202510275737.2A Pending CN120208921A (zh) 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510275737.2A Pending CN120208921A (zh) 2020-06-04 2021-05-26 癌症疗法中用于靶向降解不可靶向的kras的新型小分子

Country Status (12)

Country Link
US (1) US20230202981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161511B1 (cg-RX-API-DMAC7.html)
JP (1) JP7789016B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019937A (cg-RX-API-DMAC7.html)
CN (2) CN115768427B (cg-RX-API-DMAC7.html)
AU (1) AU2021284517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180686A1 (cg-RX-API-DMAC7.html)
IL (1) IL298672A (cg-RX-API-DMAC7.html)
MX (1) MX2022015253A (cg-RX-API-DMAC7.html)
TW (1) TWI916370B (cg-RX-API-DMAC7.html)
WO (1) WO2021245499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2025083564A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small molecule degrader as a potential anticancer
WO2025083561A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel lead small molecule inhibitors on undruggable target towards anticancer activity
WO2025083570A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule agents in overcoming tumor regression in cancers
WO2025083563A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Effective therapeutic small-molecule inhibitors for metastatic cancer
WO2025083568A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule protein kinase inhibitors for implications in cancer treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3347A1 (fr) * 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
IL161662A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
US20190284149A1 (en) * 2014-09-12 2019-09-19 Ariagen, Inc. Aryl hydrocarbon receptor modulator
CN106317055A (zh) * 2015-07-02 2017-01-11 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110885332B (zh) * 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用

Also Published As

Publication number Publication date
KR20230019937A (ko) 2023-02-09
EP4161511B1 (en) 2026-04-29
TWI916370B (zh) 2026-03-01
MX2022015253A (es) 2023-03-14
IL298672A (en) 2023-01-01
BR112022024300A2 (pt) 2023-01-24
CA3180686A1 (en) 2021-12-09
CN115768427A (zh) 2023-03-07
US20230202981A1 (en) 2023-06-29
WO2021245499A1 (en) 2021-12-09
JP7789016B2 (ja) 2025-12-19
EP4161511A1 (en) 2023-04-12
JP2023529354A (ja) 2023-07-10
CN120208921A (zh) 2025-06-27
TW202210465A (zh) 2022-03-16
EP4161511A4 (en) 2024-07-17
AU2021284517A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
CN120208921A (zh) 癌症疗法中用于靶向降解不可靶向的kras的新型小分子
He et al. Targeting cullin neddylation for cancer and fibrotic diseases
KR102427777B1 (ko) 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
JP6193268B2 (ja) Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
AU2013235425B2 (en) Inhibition of MCL-1 and/or BFL-1/A1
EP3773592B1 (en) Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
CN101910182A (zh) 抗癌剂
CN107666906A (zh) 用于治疗癌症的方法
US20190231735A1 (en) Methods for treating cancer
Hamaguchi et al. 305 POSTER DNA cross-linking and in vivo antitumour activity of the extended pyrrolo [2, 1-c][1, 4] benzodiazepine dimer SG2057 (DRG-16)
RU2839932C1 (ru) Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака
Zhu et al. Regulation of the cilia as a potential treatment for senescence and tumors: A review
AU2016296997B2 (en) Chlorobenzene substituted azaaryl compounds
US20210353631A1 (en) 1,4-Benzoxazines for the Treatment of Cancers and Other Neurodegenerative Diseases
Xu et al. Current Scenario of Hydroxamic Acid Derivatives With In Vivo Antitumor Therapeutic Potential
CN111718328A (zh) 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途
US10512631B2 (en) Chalcone compounds
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
TW201605449A (zh) 馬賽替尼治療結腸直腸癌的用途
Narayanan Anticancer Effect of Indanone-Based Thiazolyl Hydrazone Derivative on P53 Mutant Colon Cancer Cell Lines: In Vitro and in Vivo Study
Elrehany et al. Chalcone-xanthine Hybrid: Its Expected Role in Treatment of Non-small Cell Lung Cancer
WO2025083563A1 (en) Effective therapeutic small-molecule inhibitors for metastatic cancer
Mattiuzzo Pharmacological studies of novel antitumoral compounds
Xiao Discovery of Novel Tubulin Polymerization Inhibitors and Survivin Inhibitors as Potential Anticancer Agents
Sutton et al. 342 POSTER 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography is an early biomarker for tumor growth inhibition of human Colo205 xenografts by the novel and selective CENP-E inhibitor, GSK923295A

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant